
Greg Merril is a serial entrepreneur who has led more than 20 financing transactions that have raised more than $100M. He has been the founding CEO of three VC-backed health and medical product companies: Brain Sentry, Inc.; Interaction Laboratories; and Immersion Medical, Inc. While with HT Medical Systems he led the company through a $42M merger with Immersion Corp. Merril was named a Regional Ernst & Young Entrepreneur of the Year in 2007.
In 2016, Merril and his father Dr. Carl Merril, a retired NIH researcher and foremost expert on phage technology, co-founded Adaptive Phage Therapeutics (APT) in a collaboration with the U.S. Navy after the now-famed account of Tom Patterson, the first patient in the U.S. to be treated with injected phage therapy. Patterson was at the brink of life after being infected by one of the most deadly antibiotic-resistant bacteria, but beat the deadly infection using the technology that has now become the foundation of APT’s portfolio.
Become a member today
Gain the knowledge and competitive edge you need to succeed in the pharmaceutical and biopharmaceutical engineering industries and join more than 18,000 pharma professionals from around the world by becoming an ISPE Member.
Benefits include: